Deals In Depth: November 2018
Executive Summary
AstraZeneca completed another divestment, this time selling the RSV product Synagis to Swedish Orphan Biovitrum for $2.3 billion. Boston Scientific paid just over $4 billion for interventional device company BTG. Biopharma and device financing were down.